Analytics & AI products · Atlas KOL Intelligence
Know which experts shape practice, before your launch.
Atlas brings trial registries, publications, congress abstracts and industry payments together, resolves each expert to one verified profile, and shows who leads, who is rising and who is still unaligned. Built for medical and commercial teams preparing a launch.
Impact
2,000+verified lung cancer experts profiled
1 profileper expert across trials, papers, congresses and payments
5 playsready-made targeting views for your mechanism
One verified profile
Each expert matched across sources to their provider ID, so there are no duplicates or missed affiliations.
Scores you can explain
Influence built from trial leadership, publication impact and industry ties, with the evidence behind every score.
Medical and commercial
MSLs, medical affairs, marketing and market access work from the same expert list.
How it works
From input to output in 5 steps.
Experts in one indication (example)Example
1
Expert A · academic centreLeads 3 active trials · high-impact papers
Advisory board2
Expert B · community oncologyFrequent co-author · speaker
Speaker programme3
Expert C · risingNew trial investigator
MSL introduction- 1CollectTrials, publications, congresses and open payments
- 2ResolveOne profile per expert, keyed to their provider ID
- 3ReadTopics, drugs and stance from what each expert publishes
- 4ScoreInfluence across several dimensions, with evidence
- 5ActTargeting views scoped to your mechanism
Inside the product
Explore the KOL intelligence views.
A closer look at the client-provided Atlas KOL Intelligence screens. Select a thumbnail to view it above.
See more KOL Intelligence screens
Capabilities
What's inside
Identity resolutionNo duplicate experts, no missed affiliations.
Belief and topic layerWhat each expert says about drugs, biomarkers and topics, with sentiment.
Explainable influenceSee exactly which evidence drives each ranking.
Targeting playsTop voices, unaligned leaders, rising in your mechanism, rival-funded and trial investigators.
Expert profilesTrials, papers, congress talks and industry ties on one page.
New therapy areasBuilt to extend beyond lung cancer without a rebuild.
Built for
Lung cancer (NSCLC)Pre-launch teamsMedical affairsCommercial
Powers these solutions